

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75454

**Title:** Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03700188

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor, Attending Doctor

**Reviewer's Country/Territory:** Brazil

**Author's Country/Territory:** Canada

**Manuscript submission date:** 2022-01-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-02-20 13:27

**Reviewer performed review:** 2022-02-21 16:02

**Review time:** 1 Day and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## **SPECIFIC COMMENTS TO AUTHORS**

The title (Effectiveness, safety, and drug sustainability of biologics in elderly patients with Inflammatory Bowel Disease: a single center retrospective study) reflects the main subject of the manuscript. The abstract summarizes well the work described in the manuscript. The key words (IBD; Biologics; Elderly; Efficacy; Safety, Adverse events) reflect the focus of the manuscript. The manuscript adequately describes the background, present status and significance of the study. The manuscript describes methods in adequate detail. The research objectives were achieved by the experiments used in this study. The manuscript interprets the findings adequately and appropriately, and the authors showed that biologic therapies were not different with regards to drug effectiveness and safety in the elderly IBD population. The manuscript cites appropriately the latest, important and authoritative references in the introduction and discussion sections and it is well and coherently organized. The original findings were the effectiveness and safety regarding the biologic therapies in elderly IBD population. It is important for those professionals who treat those population.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75454

**Title:** Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 04091933

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor, Senior Researcher

**Reviewer's Country/Territory:** Russia

**Author's Country/Territory:** Canada

**Manuscript submission date:** 2022-01-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-02-16 21:15

**Reviewer performed review:** 2022-02-28 14:01

**Review time:** 11 Days and 16 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## **SPECIFIC COMMENTS TO AUTHORS**

Elderly patients with IBD are the most vulnerable category of patients, so the efficacy and safety of therapy, especially with biologics, are of particular interest. The authors conducted a well-designed, single-center, retrospective study that included patients over 60 years of age treated with main biologics (IFX, ADA, VDZ, UST). The reviewer has no comments on the design of the study, methods of statistical analysis, ethical statements, interpretation of the results of the study, which was performed at a high methodological level. The study's main finding, that drug resistance, safety, and efficacy of different biologics did not differ significantly in a cohort of older adults with IBD, has important clinical implications. The physicians, based on this conclusion, get more freedom in choosing a biological therapy drug and are not limited by the need to use any particular drug (for example safer or more effective). The figures and tables are well designed and reflect the main aspects of the study. Literary references are relevant, latest, without self-citation. The manuscript can be recommended for printing without any revision.